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Heparin Resistance After Cardiopulmonary Bypass
Francisco J Herrera MD, Mamatha Kadiyala MD, Stanlies D’Souza MD
Department of Anesthesiology, Baystate Medical Center/ Tufts University School of Medicine, Springfield, MA

Introduction

Treatment

Heparin resistance is defined as the inability to achieve an activated clotting time
(ACT) of >400 seconds after an adequate dose of heparin. Its incidence ranges from
3-26% (1). We present a case we recently encountered and discuss our
management.

Therapeutic
approaches
include
administering additional heparin, supplement
ATIII with FFP, supplement ATIII with an ATIII
concentrate or accept the ACT and proceed
to CPB without any additional treatment. The
effectiveness of FFP as treatment in Heparin
Resistance is limited and no studies have
shown improvement in clinical outcomes.
ATIII replacement has been shown to be
superior to FFP in increasing ACT, but
questions remain based on its increased
cost, lack of clinical outcomes improvement
and inability to reach the desired ACT in all
patients with ATIII deficiency. Accepting
below target ACT for CPB, on fixed heparin
dose regimens is often not chosen for fear of
sub-therapeutic anticoagulation.

Case Description
A 70 year old male with severe left main coronary artery disease presented for one
vessel CABG with a baseline ACT of 110. After 30,000 units of intravenous heparin,
his ACT was 380. An adequate ACT for CPB could not be achieved following 2
additional doses of 10,000 units of heparin. Adequate anticoagulation was achieved
with the transfusion of 6 units of fresh frozen plasma and subsequent administration
of 10,000 units of heparin. His intraoperative course was complicated by significant
coagulopathy, inadequate reversal with protamine and the requirement for the
transfusion of blood products.

Etiology
Deficiency of ATIII decreases the ability of heparin to inhibit thrombin and can be
either congenital or acquired in etiology. Acquired ATIII deficiency is associated with
liver disease, malnutrition, nephrotic syndrome, and previous heparin treatment.
Other factors related to heparin resistance include IV nitroglycerine, heparin binding
proteins and factor VIII among others.

Pathophysiology
Preoperative heparin (24-48 hours) is commonly thought to contribute to heparin
resistance. Heparin-AT complex binds to thrombin and this complex is rapidly
consumed and cleared via the reticuloendothelial system resulting in a ATIII level
decline by 5-7%. This decline is thought to be the mechanism by which heparin
pretreatment increases the incidence of heparin resistance. In addition to ATIII
deficiency, there are multiple other potential mechanisms that can lead to heparin
resistance that are both poorly defined and nonspecific.

Figure(s) 1 and 2. Alan Finley MD, Charles Greenberg MD. Heparin Sensitivity and Resistance:
Management During Cardiopulmonary Bypass. Anesthesia and Analgesia 2013;116(6):1210-1222.
Copyright 2015 by International Anesthesia Research Society. Used with permission.

Diagnostic Testing
• ACT (activated clotting time)
• ATIII levels (30-60 min)
• High dose thrombin time (more specific for thrombin inhibition)

Alternative Agents
Direct thrombin inhibitor: Bivalirudin (Angiomax) 1.5-2 mg/kg
followed by 0.5-5 mg/kg/h

• Heparin response curve

• Heparin level
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Conclusions
•

Identification of patients at risk for HR

•

Besides ATIII levels, multiple factors affect ACT

•

The minimum ACT required for safe conduction of CPB remains unknown

•

A rational approach should be taken to evaluate heparin resistance

•

Research is needed to confirm clinical benefits in treating heparin resistance

